Uveitis is the third leading cause of blindness worldwide, and a major one in the United States with a total prevalence of 357,791 in 2017 in the US alone, estimated DelveInsight.
Uveitis or the inflammation in the eye can be due to a pathogen such as bacteria or viruses. The most Uveitis prevalent cases were observed to be of age-group 18-59 years, whereas, the age group less than 18 years were least affected.
The present Uveitis Market size is expected to grow during the forecast period owing to the launch of upcoming therapies in the 7MM, with the US anticipated to dominate most of the Uveitis Market share.
The key players in the Uveitis market include EyePoint Pharmaceuticals, Alimera Sciences, Clearside Biomedical, Inc., Santen, Oculis S.A., and others.
For more details visit: https://www.delveinsight.com/blog/uveitis-market/